Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 29, 2009

Investigators Identify SNP Linked to Kidney Stones and Decreased Bone Mineral Density


  • Researchers at deCODE genetics and academic collaborators identified a SNP in the claudin 14 gene (CLDN14) that they believe could be responsible for kidney stones and contribute to decreased bone mineral density (BMD).  The research is published in the online edition of Nature Genetics. The paper is called “Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density.”


    Claudin 14 is one of a family of kidney cell membrane proteins that regulate ion and small solute passage between cells. Studies by the deCODE researchers in partnership with scientists in Iceland, The Netherlands, and Denmark suggest the claudin 14 SNP contributes to increased calcium excretion in urine, an indicator of bone loss.

    Additionally, homozygous carriers also had a 65% higher risk of developing kidney stones than those who didn’t have the gene variant. They also found that women who were homozygous for the SNP had decreased BMD at the hip and spine.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »